EA201490926A1 - Конструкции на основе белка, родственного липопротеинам низкой плотности, 6 (lrp6), и удлинителя полупериода существования - Google Patents

Конструкции на основе белка, родственного липопротеинам низкой плотности, 6 (lrp6), и удлинителя полупериода существования

Info

Publication number
EA201490926A1
EA201490926A1 EA201490926A EA201490926A EA201490926A1 EA 201490926 A1 EA201490926 A1 EA 201490926A1 EA 201490926 A EA201490926 A EA 201490926A EA 201490926 A EA201490926 A EA 201490926A EA 201490926 A1 EA201490926 A1 EA 201490926A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lrp6
protein
extension
low density
half period
Prior art date
Application number
EA201490926A
Other languages
English (en)
Inventor
Дэвид Дженкинс
Мин Лэй
Андреас Лев
Ли Чжоу
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201490926A1 publication Critical patent/EA201490926A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к конструкциям LRP6, которые связываются с рецептором LRP6. Конструкции LRP6 включают по меньшей мере одну LRP6-связывающую молекулу и молекулу-удлинитель полупериода существования, в результате чего конструкция LRP6 ингибирует Wnt-сигнальный каскад без потенцирования сигнала Wnt. Конструкции LRP6 также имеют увеличенный полупериод существования, что обеспечивает больше времени для достижения терапевтического эффекта.
EA201490926A 2011-11-04 2012-11-02 Конструкции на основе белка, родственного липопротеинам низкой плотности, 6 (lrp6), и удлинителя полупериода существования EA201490926A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161555848P 2011-11-04 2011-11-04
PCT/US2012/063330 WO2013067355A1 (en) 2011-11-04 2012-11-02 Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs

Publications (1)

Publication Number Publication Date
EA201490926A1 true EA201490926A1 (ru) 2014-09-30

Family

ID=47222309

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490926A EA201490926A1 (ru) 2011-11-04 2012-11-02 Конструкции на основе белка, родственного липопротеинам низкой плотности, 6 (lrp6), и удлинителя полупериода существования

Country Status (18)

Country Link
US (3) US8883735B2 (ru)
EP (3) EP3290442A1 (ru)
JP (1) JP2015502741A (ru)
KR (1) KR20140091031A (ru)
CN (1) CN104039830A (ru)
AR (1) AR088633A1 (ru)
AU (1) AU2012332263A1 (ru)
BR (1) BR112014010409A2 (ru)
CA (1) CA2854457A1 (ru)
EA (1) EA201490926A1 (ru)
ES (1) ES2666856T3 (ru)
HK (1) HK1252121A1 (ru)
IL (1) IL232309A0 (ru)
MX (1) MX2014005411A (ru)
RU (1) RU2014122602A (ru)
SG (1) SG11201401717VA (ru)
TW (1) TW201323442A (ru)
WO (1) WO2013067355A1 (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2567709T3 (en) * 2007-11-02 2018-03-12 Novartis Ag Molecules and Methods for Modulating Low-Density Lipoprotein Receptor-Related Protein 6 (LRP6)
US8927694B2 (en) * 2008-11-18 2015-01-06 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
CA2798390A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
JP2013527762A (ja) 2010-05-06 2013-07-04 ノバルティス アーゲー 治療的低密度リポタンパク質関連タンパク質６（ｌｒｐ６）抗体の組成物および使用方法
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HUE057725T2 (hu) 2011-10-03 2022-06-28 Modernatx Inc Módosított nukleozidok, nukleotidok és nukleinsavak és ezek felhasználása
WO2013067355A1 (en) 2011-11-04 2013-05-10 Novartis Ag Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243947A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2014029752A1 (en) * 2012-08-22 2014-02-27 Glaxo Group Limited Anti lrp6 antibodies
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CN103524628B (zh) * 2013-10-15 2015-01-07 张喜田 重组灵芝免疫调节蛋白与人血清白蛋白融合蛋白及其制备方法与应用
WO2015123359A1 (en) * 2014-02-11 2015-08-20 Albany Medical College Multi-functional mucosal vaccine platform
US10744207B2 (en) * 2014-05-02 2020-08-18 Acepodia, Inc. Biological complexes and methods for using same
US11142577B2 (en) 2014-09-12 2021-10-12 The Board Of Trustees Of The Leland Stanford Junior University WNT signaling agonist molecules
UA122079C2 (uk) 2015-12-04 2020-09-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Поліпептид, що специфічно зв'язується з lrp5 і lrp6
US11246905B2 (en) 2016-08-15 2022-02-15 President And Fellows Of Harvard College Treating infections using IdsD from Proteus mirabilis
CN107029211A (zh) * 2017-05-05 2017-08-11 上海市东方医院（同济大学附属东方医院） 一种用于治疗心衰保护心脏功能的药物
MA48760A (fr) 2017-05-31 2020-04-08 Boehringer Ingelheim Int Polypeptides ayant un effet antagoniste sur la signalisation wnt dans des cellules tumorales
CA3085782A1 (en) 2017-12-19 2019-06-27 Surrozen, Inc. Wnt surrogate molecules and uses thereof
CA3085785A1 (en) 2017-12-19 2019-06-27 Surrozen, Inc. Anti-lrp5/6 antibodies and methods of use
WO2023044348A1 (en) * 2021-09-14 2023-03-23 Surrozen Operating, Inc. Modulation of wnt signalling in pulmonary disorders

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60500673A (ja) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
DE3813023A1 (de) 1988-04-19 1989-11-16 Behringwerke Ag Monoklonaler antikoerper gegen pseudomonas aeruginosa, seine herstellung und verwendung
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5242813A (en) 1990-10-12 1993-09-07 The United States Of America As Represented By The Department Of Health And Human Services Mouse monoclonal antibodies specific for normal primate tissue, malignant human cultural cell lines human tumors
WO1992010591A1 (en) 1990-12-14 1992-06-25 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
JP3949712B2 (ja) 1991-12-02 2007-07-25 メディカル リサーチ カウンシル 抗体セグメントレパートリー由来でファージに表示される抗自己抗体の産生
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
AU3665893A (en) 1992-02-12 1993-09-03 United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Sequences characteristic of human gene transcription product
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
WO1994021293A1 (en) 1993-03-19 1994-09-29 Duke University Method of treatment of tumors with an antibody binding to tenascin
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
CN1117155C (zh) 1994-07-29 2003-08-06 史密丝克莱恩比彻姆有限公司 新型化合物
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
ATE331438T1 (de) 1995-01-17 2006-07-15 Brigham & Womens Hospital Rezeptorspezifischer transepithelealer transport von immunogenen
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP4271735B2 (ja) 1997-04-15 2009-06-03 メルク アンド カンパニー，インコーポレイティド 新規のｌｄｌ−レセプター
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6780609B1 (en) 1998-10-23 2004-08-24 Genome Therapeutics Corporation High bone mass gene of 1.1q13.3
US6770461B1 (en) 1998-10-23 2004-08-03 Genome Therapeutics Corporation High bone mass gene of 11q13.3
AU770667B2 (en) 1998-08-07 2004-02-26 Onyx Pharmaceuticals, Inc. CHP polypeptide, a ligand of PAK65
GB9824632D0 (en) 1998-11-10 1999-01-06 Celltech Therapeutics Ltd Biological compounds
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
WO2000043419A2 (en) 1999-01-20 2000-07-27 Rigel Pharmaceuticals, Inc. Exocytosis pathway proteins and methods of use
AU3391200A (en) 1999-03-04 2000-09-21 Corixa Corporation Compositions and methods for breast cancer therapy and diagnosis
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
EP1130094A3 (en) 1999-07-08 2001-11-21 Helix Research Institute Primers for synthesizing full length cDNA clones and their use
US20030138804A1 (en) 2000-02-03 2003-07-24 Boyle Bryan J. Methods and materials relating to novel C-type lectin receptor-like polypeptides and polynucleotides
CA2405563A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
JP2005511002A (ja) 2001-05-11 2005-04-28 ワイス 骨量変調のトランスジェニック動物モデル
US7514594B2 (en) 2001-05-11 2009-04-07 Wyeth Transgenic animal model of bone mass modulation
US20040038860A1 (en) 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
JP2005512508A (ja) 2001-05-17 2005-05-12 ゲノム　セラピューティックス　コーポレーション Ｄｋｋ媒介性相互作用を変調する試薬および方法
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
ITMI20011483A1 (it) 2001-07-11 2003-01-11 Res & Innovation Soc Coop A R Uso di composti come antagonisti funzionali ai recettori centrali deicannabinoidi
JP4199662B2 (ja) 2001-09-13 2008-12-17 財団法人化学及血清療法研究所 新規なセレノシステイン含有タンパク質
US20030194708A1 (en) 2002-04-10 2003-10-16 Minke Binnerts Human homolog of crossveinless materials and methods
PT1517921E (pt) 2002-06-28 2006-09-29 Domantis Ltd Ligandos duplamente especificos com semi-vida no soro aumentada
EP3299393A1 (en) 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
JP2006523090A (ja) 2002-12-27 2006-10-12 ドマンティス リミテッド リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
EP2357237A1 (en) 2003-05-14 2011-08-17 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
US20050084494A1 (en) 2003-05-21 2005-04-21 Darwin Prockop Inhibitors of Dkk-1
SI1639011T1 (sl) 2003-06-30 2009-04-30 Domantis Ltd Pegilirana protitelesa z enojno domeno (dAb)
JP5026072B2 (ja) 2003-07-01 2012-09-12 イミューノメディクス、インコーポレイテッド 二重特異性抗体の多価キャリヤー
US8461155B2 (en) * 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US8637506B2 (en) 2003-09-22 2014-01-28 Enzo Biochem, Inc. Compositions and methods for bone formation and remodeling
US9046537B2 (en) 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
US20080227734A1 (en) 2003-11-24 2008-09-18 Gunnar Westin Mutant Lrp5/6 Wnt-Signaling Receptors in Cancer Diagnosis, Prognosis, and Treatment
US20060094046A1 (en) 2004-02-11 2006-05-04 Arie Abo Compositions and methods relating to angiogenesis and tumorigenesis
US20060127919A1 (en) 2004-02-25 2006-06-15 Arie Abo Compositions and methods relating to cell adhesion molecule L1
CN100376599C (zh) 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
AU2005248351A1 (en) 2004-05-14 2005-12-08 The Regents Of The University Of California Methods for treating cancer using anti-Wnt2 monoclonal antibodies and siRNA
JP2008512352A (ja) 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド 新規な四価の二重特異性抗体
JP4840939B2 (ja) 2004-08-04 2011-12-21 アムジェン インコーポレイテッド Ｄｋｋ−１に対する抗体
JP2008520583A (ja) 2004-11-15 2008-06-19 マウント シナイ スクール オブ メディスン オブ ニューヨーク ユニバーシティー Ｗｎｔ自己分泌シグナル伝達を改変するための組成物および方法
JP2008528010A (ja) 2005-01-31 2008-07-31 アブリンクス ナームローゼ フェンノートシャップ 重鎖抗体の可変ドメイン配列を作出する方法
WO2006089114A2 (en) 2005-02-17 2006-08-24 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating an anthrax toxin mediated condition
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
US7811251B2 (en) 2005-10-13 2010-10-12 Tyco Healthcare Group Lp Trocar anchor
JP5525729B2 (ja) 2005-11-28 2014-06-18 ゲンマブ エー／エス 組換え一価抗体およびその作製方法
US20070248628A1 (en) 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
GEP20135917B (en) 2006-03-17 2013-09-10 Biogen Idec Inc Stabilized polypeptide compositions
JP5225266B2 (ja) 2006-05-19 2013-07-03 テバ ファーマシューティカル インダストリーズ リミティド 融合タンパク質、その使用、およびその製造方法
WO2007142987A2 (en) 2006-05-30 2007-12-13 Wisconsin Alumni Research Foundation Mammary stem cell marker
US20100129928A1 (en) 2006-07-27 2010-05-27 Roberto Polakewicz Tyrosine Phosphorylation Sites
WO2008027739A2 (en) 2006-08-28 2008-03-06 Nuvelo, Inc. Antibodies to ntb-a
AU2008245425A1 (en) 2007-04-30 2008-11-06 Washington University Methods and compositions for the treatment of cancer
AU2008254704A1 (en) 2007-05-18 2008-11-27 Medimmune, Llc IL-33 in inflammatory disease
US20090176654A1 (en) 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
US20090130105A1 (en) 2007-08-28 2009-05-21 Biogen Idec Ma Inc. Compositions that bind multiple epitopes of igf-1r
WO2009043051A2 (en) 2007-09-27 2009-04-02 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
US20100291108A1 (en) 2007-10-16 2010-11-18 Arie Abo Antibodies to irem-1
EP2211903A4 (en) 2007-10-17 2011-07-06 Nuvelo Inc CLL-1 ANTIBODY
DK2567709T3 (en) * 2007-11-02 2018-03-12 Novartis Ag Molecules and Methods for Modulating Low-Density Lipoprotein Receptor-Related Protein 6 (LRP6)
US8263743B2 (en) 2007-11-13 2012-09-11 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against TL1A
US8715941B2 (en) 2007-11-16 2014-05-06 Arca Biopharma, Inc. Antibodies to LRP6
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
CA2721093A1 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
US8716243B2 (en) 2008-05-28 2014-05-06 St. Jude Childen's Research Hospital Methods of effecting Wnt signaling through Dkk structural analysis
EP2599793A1 (en) 2008-05-29 2013-06-05 Nuclea Biotechnologies, Inc. Anti-phospho-akt antibodies
CA2731546C (en) 2008-07-23 2013-11-19 Hanmi Holdings Co., Ltd. A polypeptide complex comprising non-peptidyl polymer having three functional ends
US8927694B2 (en) 2008-11-18 2015-01-06 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
US9205177B2 (en) 2009-03-04 2015-12-08 Peytant Solutions, Inc. Stents modified with material comprising amnion tissue and corresponding processes
CA2756186A1 (en) 2009-03-24 2010-09-30 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against light and uses thereof
EP2419120A4 (en) 2009-04-08 2016-01-06 Univ California HUMAN PROTEIN CONCERNS WITH CONTROLLED SERUM PHARMACOKINETICS
CA2759233C (en) 2009-04-27 2019-07-16 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
CN102597268B (zh) 2009-09-03 2017-09-22 弗·哈夫曼-拉罗切有限公司 用于治疗、诊断和监控类风湿性关节炎的方法
US20110172398A1 (en) 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
JP2013507926A (ja) * 2009-10-14 2013-03-07 メリマック ファーマシューティカルズ インコーポレーティッド ＩＧＦ−１Ｒ及びＥｒｂＢ３シグナル伝達を標的とする二重特異的結合剤及びその使用
WO2011084714A2 (en) 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
JP6050124B2 (ja) 2010-02-19 2016-12-21 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ オクラホマ Ｗｎｔシグナル伝達経路を阻害するモノクローナル抗体ならびにその製造方法およびその使用方法
WO2011106707A2 (en) 2010-02-26 2011-09-01 Human Genome Sciences, Inc. Antibodies that specifically bind to dr3
SG184033A1 (en) * 2010-03-24 2012-10-30 Genentech Inc Anti-lrp6 antibodies
JP2013527762A (ja) 2010-05-06 2013-07-04 ノバルティス アーゲー 治療的低密度リポタンパク質関連タンパク質６（ｌｒｐ６）抗体の組成物および使用方法
CA2798390A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
WO2012175741A2 (en) 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
CN103270045A (zh) 2010-10-20 2013-08-28 霍夫曼-拉罗奇有限公司 用于调控wnt途径的方法和组合物
US20140017264A1 (en) 2010-12-10 2014-01-16 Merrimack Pharmaceuticals, Inc. Dosage and administration of bispecific scfv conjugates
WO2013067355A1 (en) 2011-11-04 2013-05-10 Novartis Ag Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs

Also Published As

Publication number Publication date
CA2854457A1 (en) 2013-05-10
USRE47860E1 (en) 2020-02-18
RU2014122602A (ru) 2015-12-10
EP2773669B1 (en) 2018-03-28
EP3252075A1 (en) 2017-12-06
US20150030617A1 (en) 2015-01-29
EP2773669A1 (en) 2014-09-10
US9173960B2 (en) 2015-11-03
ES2666856T3 (es) 2018-05-08
KR20140091031A (ko) 2014-07-18
TW201323442A (zh) 2013-06-16
AR088633A1 (es) 2014-06-25
HK1252121A1 (zh) 2019-05-17
EP3290442A1 (en) 2018-03-07
JP2015502741A (ja) 2015-01-29
US20140050725A1 (en) 2014-02-20
IL232309A0 (en) 2014-06-30
MX2014005411A (es) 2015-02-12
US8883735B2 (en) 2014-11-11
WO2013067355A1 (en) 2013-05-10
AU2012332263A1 (en) 2014-05-22
CN104039830A (zh) 2014-09-10
BR112014010409A2 (pt) 2017-04-25
SG11201401717VA (en) 2014-05-29

Similar Documents

Publication Publication Date Title
EA201490926A1 (ru) Конструкции на основе белка, родственного липопротеинам низкой плотности, 6 (lrp6), и удлинителя полупериода существования
CY1122278T1 (el) Αντι il-36r αντισωματα
CY1119577T1 (el) Συν-αγωνιστες υποδοχεα γλυκαγονης/glp-1
EA201171494A1 (ru) Миметики белка smac
CY1119979T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν τοξοειδη α και β toy clostridium difficile
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
EA201170227A1 (ru) Имидазолкарбоксамиды
CY1122978T1 (el) Αντισωματα εναντι-vla-4
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
EA201100306A1 (ru) Производные циклогексиламида и их применение в качестве антагонистов рецептора crf-1
EA201291180A1 (ru) Композиции и способы применения терапевтических антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
UA112416C2 (uk) Антитіло до fap і способи його застосування
DK2563400T3 (da) Modificerede bindeproteiner, der hæmmer VEGF-A-receptorinteraktion
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201490644A1 (ru) Терапевтические пептиды
EA201170396A1 (ru) 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
EA201590292A1 (ru) Соединения, которые являются sip-модулирующими агентами и/или atx-модулирующими агентами
GT200600186A (es) Agentes de unión
EA201390785A1 (ru) Антитела, обладающие низкой аффинностью к рецепторам гематоэнцефалического барьера, и их применения
EA201101520A1 (ru) Способы диагностики онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
UA113062C2 (xx) Похідні 5-фтор-4-іміно-3-(заміщеного)-3,4-дигідропіримідин-2(1h)ону
EA201490567A1 (ru) Новые бициклические производные дигидрохинолин-2-она
EA201390254A1 (ru) Модифицированные полипептиды релаксина и их применение